Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

SCHOTT to Strengthen Pharmaceutical Site in Hungary

Published: Monday, June 10, 2013
Last Updated: Sunday, June 09, 2013
Bookmark and Share
New maintenance facility will be opened in the Lukácsháza region.

SCHOTT Pharmaceutical Systems has announced plans to significantly expand its Hungarian site Lukácsháza that manufactures pharmaceutical primary packaging.

Investments in the mid-double-digit million euro range are planned from now until 2016.

The first step will be to open a new maintenance facility for overhauling and upgrading production machines that will create more than 30 new jobs in the Lukácsháza region.

In addition, production capacity should continue to increase in Hungary over the next few years.

SCHOTT manufactures ampoules, vials, and cartridges or so-called primary packaging for the pharmaceutical industry at its site in Lukácsháza near the Hungarian-Austrian border. The plant has continued to grow since it first opened in 1993.

Today, Lukácsháza, with its roughly 530 employees and annual production of more than 1.7 billion units, is the SCHOTT Pharmaceutical Division's single largest site.

The products manufactured in Lukácsháza are mainly exported to all parts of Europe and overseas, but also produced for the local market.

In addition to opening this global maintenance center, SCHOTT has also established a team of experts at this site that will overhaul its production machines on a regular basis and upgrade them to meet the latest technical standards.

“By doing so, we actively demonstrate our commitment to living up to the highest standards for quality and maintaining these over the long-term, in fact even for all of our global plants,” explains Dr. Jürgen Sackhoff, Vice President of SCHOTT Pharmaceutical Systems.

For Dr. Frank Heinricht, Chairman of the Board of Management, the expansion of the site in Hungary is only part of what can be considered a global investment strategy. After all, SCHOTT also intends to install new production lines in Hungary over time.

“On average, our annual production of ampoules, cartridges and vials will increase by almost half at this site,” Heinricht says and adds, “With our investment strategy, we will be helping our customers around the world to meet their quality and growth targets.”

The company also opened a new plant in India just recently and significantly expanded its capacities in Indonesia and Russia. A new joint venture in China also further expands its global manufacturing network.

Strong base in the region

SCHOTT’s expansion in Hungary also sends a powerful message to the Lukácsháza region. “We are aware of our importance as a local employer,” explains Christoph Döppes, Managing Director of the site in Lukácsháza.

“Our commitment here is long-term in nature and we are working together with the local authorities on further developing this site,” he adds.

Besides opening its new machine building facility, which received public funding support, and expanding its production capacities, SCHOTT also plans to create a number of new skilled jobs for machine builders, technicians and engineers, for instance.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

SCHOTT Committed to Further Investments in Brazilian Pharma Packaging Plant
Celebrating 80 years of ampoule manufacturing in Brazil.
Thursday, April 23, 2015
Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos